How is the Ph-like signature being incorporated into therapy?

Publication date: Available online 15 June 2017 Source:Best Practice & Research Clinical Haematology Author(s): Luke Maese, Sarah K. Tasian, Elizabeth A. Raetz Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a recently identified high risk disease subtype characterized by a gene expression profile similar to that observed in Philadelphia chromosome-positive (Ph-positive) ALL, but without an underlying BCR-ABL1 translocation. Adults and children with Ph-like ALL harbor a diversity of alterations that all lead to activated kinase signaling. Outcomes for patients with Ph-like ALL are poor, which has prompted investigation into the role of tyrosine kinase inhibitor (TKI)-based therapies for this disease. Several clinical trials are now ongoing that include screening for the Ph-like signature and treatment of patients with Ph-like ALL and targetable fusions with TKI therapy. This review examines how testing for Ph-like ALL is being incorporated into clinical trials.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research